Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2019 1
2021 1
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

5 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation.
Chan YH, Lee HF, See LC, Tu HT, Chao TF, Yeh YH, Wu LS, Kuo CT, Chang SH, Lip GYH. Chan YH, et al. Chest. 2019 Sep;156(3):529-543. doi: 10.1016/j.chest.2019.04.108. Epub 2019 May 16. Chest. 2019. PMID: 31103697
The effectiveness/safety outcomes with the four low-dose DOACs compared with warfarin were consistent with the main analysis. ...There was consistency even among high-risk subgroups and whether standard-or low-dose regimens were co …
The effectiveness/safety outcomes with the four low-dose DOACs compared with warfarin were consistent with the m …
Effectiveness and Safety of Standard- and Low-Dose Rivaroxaban in Asians With Atrial Fibrillation.
Lin YC, Chien SC, Hsieh YC, Shih CM, Lin FY, Tsao NW, Chen CW, Kao YT, Chiang KH, Chen WT, Chien LN, Huang CY. Lin YC, et al. J Am Coll Cardiol. 2018 Jul 31;72(5):477-485. doi: 10.1016/j.jacc.2018.04.084. J Am Coll Cardiol. 2018. PMID: 30049307 Free article.
In Asians, it is unclear whether low-dose rivaroxaban is equally effective as that of the standard dose or is associated with less bleeding risk. OBJECTIVES: The aim of this study was to evaluate the effectiveness and saf
In Asians, it is unclear whether low-dose rivaroxaban is equally effective as that of the standard
Standard- vs. low-dose rivaroxaban in patients with atrial fibrillation: a systematic review and meta-analysis.
Mu G, Zhang H, Liu Z, Xie Q, Zhou S, Wang Z, Wang Z, Hu K, Hou J, Zhao N, Xiang Q, Cui Y. Mu G, et al. Eur J Clin Pharmacol. 2022 Feb;78(2):181-190. doi: 10.1007/s00228-021-03226-6. Epub 2021 Oct 15. Eur J Clin Pharmacol. 2022. PMID: 34651200
PURPOSE: Low-dose rivaroxaban is often given to patients with atrial fibrillation (AF) around the world, but the rationale for its use remains unclear. ...The quality of evidence was rated ranging from very low to low for all the e …
PURPOSE: Low-dose rivaroxaban is often given to patients with atrial fibrillation (AF) around the world, …
Outcomes After Use of Standard- and Low-Dose Non-Vitamin K Oral Anticoagulants in Asian Patients With Atrial Fibrillation.
Cho MS, Yun JE, Park JJ, Kim YJ, Lee J, Kim H, Park DW, Nam GB. Cho MS, et al. Stroke. 2018 Dec 3:STROKEAHA118023093. doi: 10.1161/STROKEAHA.118.023093. Online ahead of print. Stroke. 2018. PMID: 30580716
We tried to compare effectiveness and safety outcomes of standard- and low-dose NOACs and warfarin in this population. ...Conclusions- In this cohort of East Asian patients with nonvalvular atrial fibrillation, NOACs were as …
We tried to compare effectiveness and safety outcomes of standard- and low-dose NOACs and warfarin in thi …
A Combined Pharmacometrics Analysis of Biomarker Distribution Under Treatment With Standard- or Low-Dose Rivaroxaban in Real-World Chinese Patients With Nonvalvular Atrial Fibrillation.
Zhao N, Liu Z, Xie Q, Wang Z, Sun Z, Xiang Q, Cui Y. Zhao N, et al. Front Pharmacol. 2022 Mar 18;13:814724. doi: 10.3389/fphar.2022.814724. eCollection 2022. Front Pharmacol. 2022. PMID: 35370683 Free PMC article.
Background: The rivaroxaban dose regimen for patients with nonvalvular atrial fibrillation (NVAF) is complex in Asia. ...Randomized studies should be performed to evaluate the efficacy and safety of low-dose rivaroxaban in C …
Background: The rivaroxaban dose regimen for patients with nonvalvular atrial fibrillation (NVAF) is complex in …